SABR Techniques for Metastatic Disease
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking chemotherapy agents (drugs used to treat cancer) starting one week before radiation treatment and continuing until one week after the last radiation session.
What data supports the effectiveness of this treatment for metastatic disease?
Research shows that stereotactic ablative radiotherapy (SABR) is a precise and effective treatment for controlling tumors in various organs, with local control rates of about 80%. It may also improve survival in patients with certain types of cancer that have spread to a few other areas, potentially being 'curative' in 20-25% of cases.12345
Is SABR generally safe for treating metastatic disease?
Research shows that SABR (stereotactic ablative radiotherapy) is generally safe for treating various types of metastatic disease, including in the lungs and bones. Studies have evaluated both single and multiple fraction treatments, and while the best dose is still being studied, the safety profile is considered acceptable.46789
How does the SABR treatment for metastatic disease differ from other treatments?
The SABR treatment for metastatic disease is unique because it uses high doses of radiation delivered with precision in either a single session or multiple sessions. This approach can reduce the number of hospital visits and improve patient convenience compared to traditional radiotherapy, while still effectively targeting cancer that has spread to a limited number of sites.3491011
What is the purpose of this trial?
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.
Research Team
Robert Olson
Principal Investigator
BC Cancer - Prince George
Eligibility Criteria
Adults (18+) with 1-5 oligometastatic or progressing lesions, a controlled primary tumor, and no recent malignant cancers. They must be able to undergo immobilization for SABR treatment, have a life expectancy over 6 months, and complete questionnaires. Excluded are those with serious comorbidities affecting radiotherapy safety, large brain metastases (>3.5 cm), spinal cord compression without resection, pregnant/breastfeeding individuals, or if all disease sites can't be treated.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either single fraction or multiple fraction Stereotactic Ablative Radiotherapy (SABR)
Follow-up
Participants are monitored for safety and effectiveness after treatment, including quality of life assessments and adverse event monitoring
Quality of Life Assessment
Participants complete quality of life questionnaires and may receive healthcare provider-guided interventions based on symptom screening
Treatment Details
Interventions
- Multiple fraction SABR
- QoL reporting alone
- QoL reporting, symptom screen and healthcare provider intervention
- Single fraction SABR
Find a Clinic Near You
Who Is Running the Clinical Trial?
British Columbia Cancer Agency
Lead Sponsor
London Regional Cancer Program, Canada
Collaborator
Tom Baker Cancer Centre
Collaborator
Princess Margaret Hospital, Canada
Collaborator